Search results
Results from the WOW.Com Content Network
Benzodiazepine withdrawal syndrome (BZD withdrawal) is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.
Clonazepam, sold under the brand name Klonopin among others, is a benzodiazepine medication used to prevent and treat anxiety disorders, seizures, bipolar mania, agitation associated with psychosis, obsessive–compulsive disorder (OCD), and akathisia. [11] It is a long-acting [12] tranquilizer of the benzodiazepine class. [11]
In September 2020, the U.S. Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of non-medical use, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
One such example is clobazam, a 1,5-benzodiazepine approved by the FDA in 2013 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in individuals two years or older. [ 54 ] There is no evidence that "drug holidays" or periods of abstinence reduced the risk of dependence; there is evidence from animal studies that such an ...
Most MAOIs are not approved by the FDA to treat anxiety. ... anxiety and certain symptoms of alcohol/drug withdrawal. Clonazepam. Better known as Klonopin, this medication is sometimes prescribed ...
Some packages of clonazepam were labeled with the incorrect dosage strength and National Drug Code (NDC), which is the FDA's identifier for drugs, according to Endo, Inc., the drug's manufacturer.
Librium (chlordiazepoxide) – a benzodiazepine used to treat acute alcohol withdrawal; Lithobid, Eskalith – a mood stabilizer; Loxam (escitalopram) – an antidepressant of the SSRI class; Lunesta (eszopiclone) – a non-benzodiazepine hypnotic; Luvox (fluvoxamine) – an antidepressant of the SSRI class
In the Food and Drug Administration’s (FDA) recall alert posted on Nov. 19, the pharmaceutical company is investigating and expanding its previously announced voluntary recall of Clonazepam.